Posted by Michael Wonder on 21 Jun 2020
FDA approves new Dupixent (dupilumab) pre-filled pen designed to support more convenient self-administration
19 June 2020 - 300 mg pre-filled pen expected to be available third quarter of 2020.
Regeneron Pharmaceuticals and Sanofi today announced that the U.S. Food and Drug Administration has approved a 300 mg single-dose pre-filled pen for Dupixent (dupilumab).
The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis for at-home administration.
